Feedback / Questions
XNW27011 - Astellas
https://newsroom.astellas.us/2025-05-29-Astellas-Enters-Exclusive-License-Agreement-with-Evopoint-Biosciences-for-XNW27011,-a-Novel-Clinical-stage-Antibody-Drug-Conjugate-Targeting-CLDN18-2
May 29, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next